AOD-9604 FDA Approval History At a glance FDA approval status / Never approved for any indication in the United States NDA filing history / No New Drug Application has ever been submitted to FDA Chemical identity / Synthetic peptide corresponding to amino acids 176-191 of human growth hormone, with a tyrosine residue added at the C-terminus Developer / Metabolic Pharmaceuticals Ltd (Melbourne, Australia), now defunct Clinical trial outcome / Phase IIb trial (2007) failed to meet primary efficacy endpoint for obesity FDA compounding status / Placed on Category 2 list
These include the patients health history, how bad the B12 deficiency is, and how they react to the first treatment
Axial limbs - limb weakness and pain caused by pinpointing/needles
While its still early in human research, the pathways it targets are well-documented in metabolic science, and the results so far are promising
At Gameday Mens Health, we tailor B12 dosing to your lab results, symptoms, and lifestyle needs, ensuring you get just the right amount, at just the right time
That copper binding is not incidental
